Phosphodiesterase Screening & Profiling
There is a vast array of pharmacological applications for PDE inhibition. Inhibition of this enzyme has been used to treat a wide variety of disorders such as asthma, COPD, schizophrenia, and malaria.
Accelerate your drug discovery program with our cell-based PDE screening and profiling services.
Available cell lines:
We offer rapid and dependable cell signalling pathway screening services of small molecules, peptides and antibodies against requested targets by IC50 or EC50 determination.
Cell-based & biochemical assays:
|ARE Reporter (Nrf2 antioxidant pathway)||NFAT Reporter||RARγ Reporter|
|Gli Reporter (Hedgehog Pathway) (EC50 or IC50)||Notch1/CSL Reporter (Notch signaling pathway)||SBE Reporter (TGF/SMAD signaling pathway) (EC50 or IC50)|
|ISRE Reporter (JAK Pathway) (EC50 or IC50)||Myc Reporter (Myc signaling pathway)||SRE Reporter (ERK pathway) (EC50 or IC50)|
|kRas (G12C)||RARα reporter||TEAD Reporter (Hippo pathway)|
|NF-κB reporter||RARβ reporter||TCF/LEF Reporter (Wnt Signaling, Lithium Chloride Dependent) (EC50 or IC50)|
Immunotherapy Screening & Profiling
AMSBIO offers quality immunotherapy screening services of small molecules, peptides, and antibodies against requested targets by IC50 determination.
CAR-T Cell Research
With our expertise in monoclonal antibody development (rabbit and mouse), we can help you design, plan and execute your CAR-T study, whether you are in the preclinical, clinical or proof of concept stage.
Tumor Cell Proliferation
We provide tumor cell proliferation assay services to help determine the IC50 values of your compounds of interest in whole cell assays. We offer over 20 different normal and tumor cell lines for cell screening and proliferation assays.
|MIA PaCa-2||Human||Pancreatic carcinoma|
|UTSCC5||Human||Squamous cell carcinoma|
|UTSCC8||Human||Squamous cell carcinoma|
|UTSCC9||Human||Squamous cell carcinoma|
|UTSCC10||Human||Squamous cell carcinoma|
|UTSCC14||Human||Squamous cell carcinoma|
|UTSCC16A||Human||Squamous cell carcinoma|
|UTSCC16B||Human||Squamous cell carcinoma|
|UTSCC24A||Human||Squamous cell carcinoma|
|Jurkat||Human||Acute T-cell leukemia|
In partnership with ScreenIn3D, AMSBIO provides next-generation, high quality screening services that help drug developers to validate the effectiveness of their compounds and treatment on physiologically relevant, preclinical in vitro models of disease. Our unique ex vivo microfluidic platform offers advanced and customisable drug screening assays using primary cells and human tissue in a 3D environment.
We can offer the opportunity to study the effect of drugs on various cell types as well as their interactions in a 3D microenvironment.
Patient-derived tissue generally contains several cell types, such as cancer cells, stromal cells, endothelial cells and immune infiltrate. Our technology allows the generation of multicellular spheroids which contain tumor cells and stromal cells, as well as various immune cells. This provides a highly relevant platform for your early to late stage drug development and profiling projects.
Single & combination compound screening
We can monitor the efficacy of your compounds tested in isolation or in combination in a cost-effective manner on arrays of spheroids.
We can assess the efficacy of your compound in vitro mimicking clinical protocols, giving you confidence to progress to in vivo studies. Combinations of several agents have been a hallmark of chemotherapy. We are able to provide multiple formats for testing combinations of two or more agents.
We will work with you to develop the assay that you need.
The composition of the multicellular structures can be varied over time, sequentially adding cells at any point during the experiment. By testing drugs on spheroids consisting of many cell types, the effect of your molecule on all cell types of interest can be examined in a physiologically relevant 3D microenvironment. Our microfluidic platform facilitates extended periods of culture, offering the ability to create bespoke drug testing regimens to a large number of spheroids simultaneously.
Chemo-radio combination studies
We can monitor the efficacy of your compounds tested in combination with radiotherapy.
Radio-chemotherapy combination treatment is the current standard of care for a range of cancer types to reduce tumour size and metastasis. We can provide X-ray irradiation to multicellular tumour spheroids, either alone or in combination with commonly used adjuvant chemotherapy and your compound of interest.